Publications

Li B, Luo X, Deng B, Wang J, McComb DW, Shi Y, Gaensler KM, Tan X, Dunn AL, Kerlin BA, Dong Y. An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano letters. 2015. PMID: 26529392


Karin Gaensler, MD

Bol GM, Xie M, Raman V. DDX3, a potential target for cancer treatment. Volume 14 Molecular cancer. 2015. PMID: 26541825


Guus Bol, MD, PhD

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA dermatology. 2015. PMID: 26222619


Alain Algazi, MD

Tempero M. At Last: Getting Paid to Think! Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 26553759


Margaret Tempero, MD

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA dermatology. 2015. PMID: 26222619


Adil Daud, MD

Mabray MC, Cohen BA, Villanueva-Meyer JE, Valles FE, Barajas RF, Rubenstein JL, Cha S. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. AJR. American journal of roentgenology. 2015. PMID: 26496556


James Rubenstein, MD, PhD

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA dermatology. 2015. PMID: 26222619


Matthew Gubens, MD, MS

Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA oncology. 2015. PMID: 26204261


Mark Moasser, MD

Jiang H, Rugo HS. Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Therapeutic advances in medical oncology. 2015. PMID: 26557900


Hope Rugo, MD

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. Journal of the National Comprehensive Cancer Network : JNCCN. 2015. PMID: 26553764


Alan Venook, MD

Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of hematology & oncology. 2015. PMID: 26518223


Katy Tsai, MD

Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of hematology & oncology. 2015. PMID: 26518223


Adil Daud, MD

Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast cancer research and treatment. 2015. PMID: 26520840


John Park, MD

Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast cancer research and treatment. 2015. PMID: 26520840


Hope Rugo, MD

Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast cancer research and treatment. 2015. PMID: 26520840


Michelle Melisko, MD

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The New England journal of medicine. 2015. PMID: 26510020


Alan Ashworth, PhD

Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology. 2015. PMID: 27141383


Lawrence Fong, MD

Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE. GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology. 2015. PMID: 27141383


Li Zhang, PhD

Hrustanovic G, Bivona TG. RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Molecular & cellular oncology. 2015. PMID: 27308613


Trever Bivona, MD, PhD

Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. PMID: 26503204


Hope Rugo, MD